RTX-224 Monotherapy in Patients With Solid Tumors

Summary

This is an open-label, multidose, first-in-human (FIH), Phase 1/2 study of RTX-224 for the treatment of patients with relapsed or refractory (R/R), or locally advanced solid tumors.

Timeline

Start

2022-01-12

Primary completion

2022-11-30

Completion

2022-11-30

Outcome

Outcome not reported

Stopped: “The Sponsor terminated study after dosing 2 dose groups (7 pts) and closed trial on 11/30/22. RTX-224 was well-tolerated with no DLTs, no related deaths, SAEs or Gr. 3/4 AEs and cleared rapidly (w/in 10 min).”

Drugs

Indications